QIAGEN N.V. Files Q2 2025 6-K Report

Ticker: QGEN · Form: 6-K · Filed: Aug 7, 2025 · CIK: 1015820

Qiagen N.V. 6-K Filing Summary
FieldDetail
CompanyQiagen N.V. (QGEN)
Form Type6-K
Filed DateAug 7, 2025
Risk Levellow
Pages4
Reading Time5 min
Key Dollar Amounts$498.4 million, $498.5 million, $500.0 million
Sentimentneutral

Sentiment: neutral

Topics: quarterly-report, foreign-private-issuer, sec-filing

Related Tickers: QIAGEN

TL;DR

QIAGEN dropped its Q2 2025 6-K, check it for updates.

AI Summary

QIAGEN N.V. filed a Form 6-K on August 7, 2025, reporting on its quarterly period ended June 30, 2025. The filing is a report of a foreign private issuer and includes information on other matters, signatures, and an exhibit index.

Why It Matters

This filing provides an update on QIAGEN's financial and operational status for the second quarter of 2025, which is important for investors to assess the company's performance.

Risk Assessment

Risk Level: low — This is a routine quarterly filing (6-K) that provides standard financial reporting information.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the company has made or is required to make public pursuant to the laws of its home country, or that it has filed or will file with a stock exchange.

What period does this specific 6-K filing cover?

This filing covers the quarterly period ended June 30, 2025.

What is the filing date of this 6-K report?

This 6-K report was filed on August 7, 2025.

Is QIAGEN N.V. required to file annual reports under Form 20-F or Form 40-F?

QIAGEN N.V. indicates it files annual reports under cover of Form 20-F.

What are the main sections included in this 6-K filing?

The table of contents indicates the filing includes 'Other Information', 'Signatures', and an 'Exhibit Index'.

Filing Stats: 1,147 words · 5 min read · ~4 pages · Grade level 12.7 · Accepted 2025-08-06 21:50:23

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. QIAGEN N.V. By s Roland Sackers Roland Sackers Chief Financial Officer Date August 6, 2025 5 Table of Contents EXHIBIT INDEX Exhibit No. Exhibit 99.1 Press Release dated August 5, 2025 6

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing